Van ECK Associates Corp Has $22.79 Million Stock Holdings in IQVIA Holdings Inc. $IQV

Van ECK Associates Corp increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 117,970 shares of the medical research company’s stock after buying an additional 2,171 shares during the quarter. Van ECK Associates Corp owned 0.07% of IQVIA worth $22,794,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of IQV. Nissay Asset Management Corp Japan boosted its position in IQVIA by 3.8% during the 2nd quarter. Nissay Asset Management Corp Japan now owns 22,745 shares of the medical research company’s stock worth $4,395,000 after acquiring an additional 839 shares during the period. Lombard Odier Asset Management Europe Ltd acquired a new position in shares of IQVIA in the 2nd quarter valued at about $11,689,000. Ratan Capital Management LP purchased a new stake in shares of IQVIA in the second quarter worth approximately $646,000. Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in shares of IQVIA during the second quarter worth approximately $122,000. Finally, Rakuten Investment Management Inc. purchased a new position in IQVIA during the second quarter valued at approximately $5,307,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider W Richard Staub sold 5,500 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider owned 20,999 shares in the company, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 12,913 shares of company stock valued at $3,098,793. Company insiders own 1.70% of the company’s stock.

IQVIA Price Performance

Shares of IQV opened at $260.48 on Monday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The firm has a market cap of $42.88 billion, a PE ratio of 32.32, a PEG ratio of 2.24 and a beta of 1.18. The firm’s 50 day moving average price is $222.14 and its 200 day moving average price is $189.59. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $265.25.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a share repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on IQV. Barclays reiterated an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. Robert W. Baird boosted their price target on shares of IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday. JPMorgan Chase & Co. increased their price objective on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Finally, BMO Capital Markets lifted their price objective on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.